NDLI: In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.

Please wait, while we are loading the content...

Year: 2017 Volume: 39

Year: 2016 Volume: 38

Year: 2015 Volume: 37

Year: 2014 Volume: 36

Year: 2013 Volume: 35

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Issue: 12

Year: 2008 Volume: 30 Issue: 11

Year: 2008 Volume: 30 Issue: 10

Year: 2008 Volume: 30 Issue: 9

Year: 2008 Volume: 30 Issue: 8

Year: 2008 Volume: 30 Issue: 6

Year: 2008 Volume: 30 Issue: 5

Role of corticosteroids in the management of acute respiratory distress syndrome.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Rotigotine transdermal system for the treatment of Parkinson's disease.

Ambrisentan for the management of pulmonary arterial hypertension.

Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.

Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial.

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study.

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.

Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study.

Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive- extended-release and immediate-release tablets: a randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects.

In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.

Effects of aminaftone 75 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis.

Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature.

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.

Health technology assessment: regulators or payers--who will take the lead?

Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial.

Year: 2008 Volume: 30 Issue: 3

Year: 2008 Volume: 30 Issue: 2

Year: 2008 Volume: 30 Issue: 1

Year: 2008 Volume: 30 Issue: Supplementary C

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Petersson, Britt Schönwandt, Anna B. Thornstfeldt, Preben Nedergaard, Hanne Jensen, Michael Bech Thornstergaard, Per B. Norsell, Tina Bjerre, Jens
Description	Country affiliation: Denmark Author Affiliation: Petersson B ( Biopharm API and DP Support, Novo Nordisk A/S, Gentofte, Denmark. bpss@novonordisk.com)
Abstract	BACKGROUND: Recombinant activated factor VIIa (rFVIIa) is indicated for on-demand treatment of bleeding and the prevention and treatment of surgical bleeding in patients with hemophilia A or B who have antibodies to coagulation factors VIII or IX. The currently approved single-use formulation of rFVIIa is freeze dried and is stable for up to 3 years when stored at 2 degrees C to 8 degrees C (36 degrees F-46 degrees F). A new formulation has been developed that is stable for up to 2 years when stored at temperatures up to 25 degrees C (77 degrees F). This formulation does not require refrigerated storage and does not have to be brought to room temperature before use. Both formulations must be reconstituted before use. The original formulation is reconstituted with sterile water for injection (SWFI), whereas the new formulation is reconstituted with a solvent containing histidine. OBJECTIVE: This study examined the stability of the 2 formulations of rFVIIa after being dissolved in inappropriate types or volumes of solvent. Although the new formulation is expected to take the place of the original formulation, inappropriate reconstitution may accidentally occur in the transition period during which both products are available. METHODS: A series of in vitro experiments was designed to determine the chemical and physical stability of the 2 formulations under 4 sets of conditions. In part 1, the new formulation was reconstituted with appropriate volumes of inappropriate solvent (SWFI or physiologic saline) and in the appropriate histidine solvent. In part 2, the new formulation was reconstituted in inappropriate volumes of saline, histidine solvent, or a mixture of saline and histidine solvent. In part 3, the original formulation was reconstituted with histidine solvent. In part 4, the new formulation was mixed with the original formulation, each correctly reconstituted but subsequently pooled. RESULTS: The active substance, rFVIIa, remained chemically and physically stable for up to 6 hours of storage at 25 degrees C (77 degrees F) or for up to 24 hours of storage at 5 degrees C (41 degrees F) in the experiments in which an inappropriate type or volume of solvent was used. However, the concentration of rFVIIa stated in the product labeling was not achieved when the product was reconstituted in the incorrect volume of solvent. No changes in rFVIIa concentration, rFVIIa aggregates (dimers, oligomers, or polymers), degradation products, oxidized forms, coagulation activity, clarity, or pH were seen after storage of the reconstituted products. CONCLUSION: Based on the results of these experiments, the 2 rFVIIa products should be reconstituted using the appropriate solvent at the correct volume.
File Format	HTM / HTML
ISSN	01492918
Issue Number	5
Volume Number	30
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2008-05-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Coagulants Chemistry Factor Viia Drug Stability Histidine Recombinant Proteins Solvents Journal Article Research Support, Non-u.s. Gov't
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in